Tirzepatide Weight Loss for MRD+ Early Breast Cancer

NCT06517212 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication tirzepatide can help people with early-stage breast cancer lose weight.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 48 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2024-11 · est. completion 2030-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06517212 ↗

Description as written by the study sponsor.

This trial aims to asses if tirzepatide-induced weight loss will lead to metabolic and hormonal changes in hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-), node-positive (N+) high risk early breast cancer patients with obesity or overweight, inhibiting the growth and survival of micrometastatic disease and leading to clearance of tumor-informed circulating tumor DNA (ctDNA) and freedom from the development of metastatic disease.

Treatments tested

Tirzepatide also known as ZepBound Drug

Patients will receive tirzepatide once weekly for up to 2 years.

Main thing measured	ctDNA efficacy
Sponsor	Baylor Research Institute
Conditions studied	Breast Cancer, Breast Neoplasms, Breast Cancers
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06517212 ↗